Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Maintenance for Acute Myeloid Leukemia
NCT07392242Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ivosidenib in acute myeloid leukemia (AML), sponsored by Memorial Sloan Kettering Cancer Center. Started Jan 2026; status: recruiting.
02
Drugs
ivosidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07392242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07392242.